ABBOTT BIOTHERAPEUTICS CORP.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
C07K PEPTIDES 9127
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 7248
 
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 594
 
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 247
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 2165
 
 
 
A01K ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS147
 
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 194
 
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 198
 
 
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 1124

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

  • No Recent Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
8937159 Anti-HER2 antibodies and their usesDec 15, 10Jan 20, 15[C07K]
8017116 Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesisAug 17, 07Sep 13, 11[A61K, C12N, A61P]
7935793 Treatment of inflammatory bowel diseases with anti-IP-10 antibodiesNov 10, 04May 03, 11[A61K, C07K]
7842293 Compositions and methods using anti-CS1 antibodies to treat multiple myelomaAug 07, 07Nov 30, 10[A61K, C12N, A61P]
7365168 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisApr 08, 05Apr 29, 08[C12P]
7361740 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisApr 09, 04Apr 22, 08[C12P]
7276372 Antibodies against GPR64 and uses thereofDec 19, 03Oct 02, 07[C12N]
7217797 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisOct 15, 03May 15, 07[C12P]
7183390 Humanized antibodies to gamma-interferonNov 13, 01Feb 27, 07[C07K]
6750013 Methods for detection and diagnosing of breast cancerDec 21, 00Jun 15, 04[C07H, C12Q, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2013/0058,921 USE OF AUTOLOGOUS EFFECTOR CELLS AND ANTIBODIES FOR TREATMENT OF MULTIPLE MYELOMAAbandonedOct 30, 09Mar 07, 13[A61K, A61P]
2011/0165,154 COMPOSITIONS AND METHODS USING ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMAAbandonedOct 12, 10Jul 07, 11[A61K, C12N, A61P]
2011/0104,153 USE OF IMMUNOREGULATORY NK CELL POPULATIONS FOR PREDICTING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTSAbandonedOct 29, 10May 05, 11[A61K, C12Q, A61P]
2011/0070,231 STABLE LIQUID PHARMACEUTICAL FORMULATION OF IGG ANTIBODIESAbandonedNov 24, 10Mar 24, 11[A61K]
2011/0053,209 USE OF AN IMMUNOREGULATORY NK CELL POPULATION FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTSAbandonedAug 31, 10Mar 03, 11[C12Q]
2010/0291,111 Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell ProliferationAbandonedDec 18, 09Nov 18, 10[A61K, A61P]
2010/0273,204 METHODS FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTSAbandonedApr 27, 10Oct 28, 10[C12Q]
2010/0074,841 Compositions Against Cancer Antigen LIV-1 and Uses ThereofAbandonedNov 19, 09Mar 25, 10[A61K, C12N, C07K]
2010/0055,098 METHOD FOR TREATING MULTIPLE SCLEROSIS PATIENTS WITH ANTI-IL2R ANTIBODIESAbandonedAug 28, 09Mar 04, 10[A61K]
7662384 Use of anti-α5β1 antibodies to inhibit cancer cell proliferationExpiredMar 24, 05Feb 16, 10[A61K]
7381803 Humanized antibodies against CD3ExpiredJul 18, 00Jun 03, 08[C07K]
2003/0138,417 Stable liquid pharmaceutical formulation of IgG antibodiesAbandonedNov 08, 02Jul 24, 03[A61K]
2002/0194,631 Method of treating psoriasis using anti-interleukin 12 antibodyAbandonedMar 26, 02Dec 19, 02[A61K, A01K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.